other material
confidence high
sentiment positive
materiality 0.75
Arbutus Phase 2a: imdusiran+IFN yields sustained undetectable HBsAg in 33% at 24 weeks
Arbutus Biopharma Corp
- 33.3% (4/12) on 48wk imdusiran + 24wk IFN had undetectable HBsAg at EOT, sustained 24wk post-treatment.
- All six patients with sustained HBsAg loss seroconverted with high anti-HBsAg antibodies (43.8 to >1,000 mIU/mL).
- Two of six patients stopped all therapy and maintain undetectable HBsAg and HBV DNA at 12 weeks off therapy.
- No SAEs related to imdusiran or IFN; most common TEAEs were transient ALT elevations and injection site bruising.